21 de febrero de 2017 / 13:31 / hace 10 meses

BRIEF-Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study

Feb 21 (Reuters) - Xbiotech Inc:

* Xbiotech reports affirmative interim analysis of global phase 3 colorectal cancer study

* Xbiotech Inc - IDMC reported that FDA fast-tracked study had no safety concerns

* Xbiotech Inc - FDA fast-tracked study’s indications of efficacy were sufficient to recommend proceeding with study without modification Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below